- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05025072
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy Volunteers
This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose crossover study to compare and assess the bioequivalence, safety, tolerability and pharmacokinetics of hydroxycarbamide dispersible tablets (20 x 50 mg) (test IMP) and hydroxycarbamide film-coated tablet (1000 mg) (reference IMP) following single-dose administration. Thirty (30) healthy male and female participants, between 18 and 50 years of age are planned to participate in the study.
Study participants will be randomised to one of the 2 possible combination sequences. After each treatment administration, blood samples will be collected at specific time points to assess the Pharmacokinetics (PK) parameters.
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Merthyr Tydfil, 영국
- Simbec-Orion Clinical Pharmacology
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy male and female participants, between 18 and 50 years of age, inclusive.
- Female participant of childbearing potential willing to use a highly effective method of contraception, if applicable from the first dose until 3 months after the last dose of IMP.
- Female participant of non-childbearing potential. For the purposes of this study, this is defined as the participant being amenorrhoeic for at least 12 consecutive months or at least 4 months post-surgical sterilisation.
- Female participant with a negative pregnancy test at Screening.
- Male participant (and partner of child bearing potential) willing to use a highly method of contraception, if applicable from first dose until 3 months after last dose of IMP.
- Participant with a BMI of 18-29.9 kg/m2.
- No clinically significant history of previous allergy / sensitivity to hydroxycarbamide or any of the excipients contained within the IMP(s).
- No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP.
- Participant with a negative urinary DOA screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP.
- Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
- No clinically significant abnormalities in 12-lead ECG determined within 28 days before the first dose of IMP.
- No clinically significant abnormalities in vital signs determined within 28 days before the first dose of IMP.
- Participant must be available to complete the study.
- Participant must satisfy an Investigator about his/her fitness to participate in the study.
- Participant must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives prior to the first dose of IMP.
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
- A clinically significant history of drug or alcohol abuse within the past two years.
- Inability to communicate well with the Investigators.
- Participation in a New Chemical Entity clinical study within the previous 3 months or five half-lives whichever is the longest, or a marketed drug clinical study within the 30 days or five half-lives whichever is the longest, before the first dose of IMP.
- Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
- Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to Screening or users of cigarette replacements
- Female participants who are pregnant, breastfeeding or lactating.
- Participants who have received any live or attenuated vaccine within 28 days of the first dose of IMP, or who are planning to receive a vaccine up to 28 days after receiving the last dose of IMP in Treatment Period 2.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Sequence A
Hydroxycarbamide dispersible tablets (20 x 50 mg) then Hydroxycarbamide film-coated tablet (1000 mg) |
Hydroxycarbamide dispersible tablets (20 x 50 mg) Hydroxycarbamide film-coated tablet (1000 mg) |
|
실험적: Sequence B
Hydroxycarbamide film-coated tablet (1000 mg) then Hydroxycarbamide dispersible tablets (20 x 50 mg) |
Hydroxycarbamide dispersible tablets (20 x 50 mg) Hydroxycarbamide film-coated tablet (1000 mg) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cmax
기간: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The observed maximum concentration (Cmax) in plasma |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
AUC0-infinity
기간: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The AUC from time 0 to infinity |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
AUC0-t
기간: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The area under the plasma concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t) |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Tmax
기간: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The time at which Cmax is apparent |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
t1/2
기간: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The terminal elimination half-life |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
Adverse Events
기간: Day-1, Day1, Day2 of each treatement period, and up to the end of study visit which occured 1 to 3 days post last IMP administration for a maximum duration of approximately 7 weeks per participant.
|
Number of participants with Adverse Events |
Day-1, Day1, Day2 of each treatement period, and up to the end of study visit which occured 1 to 3 days post last IMP administration for a maximum duration of approximately 7 weeks per participant.
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Annelize Koch, MD, Simbec-Orion Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .